1. Journal of Thoracic Oncology
Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors 
Lizza E.L. Hendriks, MD, PhD, Clemence Henon, MD, Edouard Auclin, MD, PhD, Laura Mezquita, MD, PhD, Roberto Ferrara, MD, Clarisse Audigier-Valette, MD, Julien Mazieres, MD, PhD, Corentin Lefebvre, MD, Audrey Rabeau, MD, Sylvestre Le Moulec, MD, Sophie Cousin, MD, Boris Duchemann, MD, Cecile le Pechoux, MD, Angela Botticella, MD, Samy Ammari, MD, MSc, Anas Gazzah, MD, Caroline Caramella, MD, Julien Adam, MD, PhD, Emmanuèle Lechapt, MD, David Planchard, MD, PhD, Dirk De Ruysscher, MD, PhD, Anne-Marie Dingemans, MD, PhD, Benjamin Besse, MD, PhD 
Journal of Thoracic Oncology 
DOI: /j.jtho
Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
CONSORT diagram: patient inclusion. ICI: immune checkpoint inhibitor; LM: leptomeningeal metastasis; BM: brain metastasis.
Journal of Thoracic Oncology DOI: ( /j.jtho )
Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Kaplan-Meier curves for progression-free survival (A) and overall survival (B) according to presence of brain metastases. met, metastasis.
Journal of Thoracic Oncology DOI: ( /j.jtho )
Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions